Scilex Holding (SCLX) Total Liabilities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Total Liabilities of $547.7 million for Q1 2026, up 88.56% year-over-year from $290.5 million in Q1 2025, and down 5.03% on a QoQ basis from $576.7 million in Q4 2025.
Scilex Holding (SCLX) Total Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Total Liabilities for 7 consecutive years, with $547.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 88.56% year-over-year to $547.7 million; the TTM figure through Mar 2026 stood at $547.7 million (up 88.56% YoY), while the FY2025 annual figure was $576.7 million, up 101.94% from the prior year.
- Total Liabilities came in at $547.7 million for Q1 2026 at Scilex Holding, down from $576.7 million in the prior quarter.
- The five-year high for Total Liabilities was $576.7 million in Q4 2025, with the low at $11.1 million in Q1 2022.
- Average Total Liabilities over 5 years is $249.2 million, with a median of $281.0 million recorded in 2024.
- Across the five-year window, Total Liabilities tumbled 83.34% in 2022 and soared 1898.54% in 2023, its largest moves.
- Year by year, Total Liabilities stood at $50.3 million in 2022, then soared by 445.35% to $274.2 million in 2023, then grew by 4.14% to $285.6 million in 2024, then soared by 101.94% to $576.7 million in 2025, then slipped by 5.03% to $547.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $547.7 million, $576.7 million, and $455.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 85.38 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.71 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 143.12 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -66.63 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 82.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 547.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 547.71 Mn |
| Dec 31, 2025 | 576.73 Mn |
| Sep 30, 2025 | 455.60 Mn |
| Jun 30, 2025 | 332.74 Mn |
| Mar 31, 2025 | 290.46 Mn |
| Dec 31, 2024 | 285.59 Mn |
| Sep 30, 2024 | 311.75 Mn |
| Jun 30, 2024 | 319.24 Mn |
| Mar 31, 2024 | 281.03 Mn |
| Dec 31, 2023 | 274.25 Mn |
| Sep 30, 2023 | 243.20 Mn |
| Jun 30, 2023 | 116.05 Mn |
| Mar 31, 2023 | 74.98 Mn |
| Dec 31, 2022 | 50.29 Mn |
| Sep 30, 2022 | 12.17 Mn |
| Jun 30, 2022 | 52.88 Mn |
| Mar 31, 2022 | 11.10 Mn |
| Dec 31, 2021 | 301.81 Mn |
| Sep 30, 2021 | 10.09 Mn |
| Jun 30, 2021 | 8.90 Mn |